Mimedx Group (MDXG) Stock News

MiMedx Group, Inc. (Nasdaq: MDXG) announced a peer-reviewed study demonstrating that its PURION® processed dHACM (EPIFIX®) provides a significantly lower risk for infection and scarring compared to traditional autologous tissue methods in Mohs micrographic surgeries. The study, involving 286 patients, revealed those using placental allografts were 12 times less likely to experience post-surgical infections and 19 times less likely to have unacceptable scarring. The findings validate the use of placental allografts as a safer reconstruction alternative, particularly for older patients with multiple skin cancer surgeries.

MiMedx Group reported third quarter 2021 net sales of $63.1 million, a slight decline from $64.3 million in 3Q20. Adjusted net sales of $62.8 million reflect a 13% increase in core portfolio sales year-over-year. The company recorded a net loss of $2.3 million, significantly less than $19.4 million in the previous year. Adjusted EBITDA was $6.8 million. The outlook for 2021 projects adjusted net sales between $245 million to $255 million, signaling potential growth in surgical applications and ongoing clinical efforts.

Marietta, Ga. — MiMedx Group (Nasdaq: MDXG) announced its participation in upcoming virtual investor conferences. CEO Timothy R. Wright, CFO Peter M. Carlson, and CCO Rohit Kashyap will engage in fireside chats at the Credit Suisse 30th Annual Healthcare Conference on November 9, 2021, at 3:30 PM ET, and the Canaccord Genuity MedTech Forum on November 18, 2021, at 9:30 AM ET. Webcasts will be available via the company’s website. MiMedx specializes in regenerative medicine utilizing amniotic tissue for wound care and musculoskeletal conditions.

MIMEDX announced two peer-reviewed studies on micronized dehydrated human amnion chorion membrane (mdHACM) for treating osteoarthritis and tendinopathy. The studies reveal mdHACM's potential to regulate inflammatory processes and enhance tissue repair. The first study, published in Osteoarthritis and Cartilage Open, highlights mdHACM's chondroprotective effects by inhibiting key signaling pathways in chondrocytes. The second study in the Journal of Biomedical Materials Research, Part B, shows mdHACM diminishes inflammation and promotes healing in chronic tendon injuries, suggesting its role in regenerative medicine.

MiMedx Group, Inc. (Nasdaq: MDXG) will announce its third-quarter financial results for the period ending September 30, 2021, on November 2, 2021, after market close. A webcast and conference call are scheduled for November 3, 2021, at 8:30 AM ET to discuss these results. MiMedx specializes in regenerative medicine, particularly through the use of amniotic tissue. The company has supplied over two million allografts, focusing on treating acute and chronic non-healing wounds while developing a pipeline for degenerative musculoskeletal conditions.

Marietta, Ga. – MiMedx Group, Inc. (Nasdaq: MDXG) announced a virtual Investor Day on December 7, 2021, at 9:00 a.m. ET. The event will showcase the Company’s late-stage pipeline in musculoskeletal conditions and its advanced wound care business. Further registration details will be shared soon. A live webcast is accessible via the Company’s Investors section at www.mimedx.com, with a replay available post-event. MiMedx specializes in amniotic tissue for regenerative medicine, addressing severe non-healing wounds and musculoskeletal pain.

Net Health announced a partnership with MiMedx Group, Inc. (Nasdaq: MDXG) to enhance the insurance verification process for MIMEDX's tissue-based products. The integration of MIMEDX into Net Health's Wound Care software enables hospital and outpatient providers to submit electronic insurance verification forms efficiently. This collaboration aims to reduce administrative burdens on clinicians and expedite insurance approvals. MIMEDX's EPIFIX® product is covered by all national commercial payors, further emphasizing the significance of this partnership in improving patient access to advanced wound care solutions.

MIMEDX announced interim results from its Phase 2B Knee Osteoarthritis (KOA) trial and Phase 3 Plantar Fasciitis (PF) trial. The KOA trial, involving 446 patients, did not meet primary endpoints but showed varied efficacy signals among cohorts, prompting plans for Phase 3 confirmatory studies. The PF trial also failed to meet its primary endpoint, leading to the decision against a Biologics License Application (BLA) at this time. Both trials demonstrated safety with no significant adverse events. MIMEDX intends to consult with the FDA regarding future study directions.

MiMedx Group (Nasdaq: MDXG) has announced the effective shelf registration statement on Form S-3 with the SEC, allowing the sale of up to $350 million in various securities over the next three years. Details regarding future offerings will be disclosed at the time of such offerings. The company intends to announce top-line results from its clinical trials involving micronized dehydrated human amnion chorion membrane (mdHACM) for knee osteoarthritis and plantar fasciitis later this summer. Investors are cautioned to consider potential risks and uncertainties associated with the forward-looking statements.